Le Lézard
Classified in: Health, Science and technology, Business
Subjects: JVN, SCZ, DEI

Axxess Enables Clients to Provide Cognitive Impairment Services Through Collaborative CAMP Partnership


More than 16 Million Americans Live with Cognitive Impairment

DALLAS, Dec. 1, 2022 /PRNewswire/ -- Helping care at home organizations expand their service lines and provide high-quality patient care, Axxess now enables clients to offer cognitive impairment services through a new strategic partnership with Cognitive Assessment and Memory Program (CAMP). CAMP combines digital therapeutics with app-based technology and artificial intelligence to provide assessments and treatments for mild to moderate cognitive impairment.

"Care at home organizations with increasing costs are looking to expand their service lines, and caring for patients with cognitive impairments is a natural opportunity," said Chris Taylor, Axxess Senior Vice President of Channel Partnerships. "We are pleased to partner with CAMP to provide our clients more innovative ways to grow their business and serve patients in their communities who need them most." 

CAMP partners with home health organizations to expand patient reach and services. Physicians can order CAMP for their patients, who are then given a cognitive assessment and a custom treatment plan consisting of cognitive exercises. In-depth reports provide detailed patient progress and insight. Because the program is tailor-made for each patient, using CAMP can improve physician relationships and decrease hospitalizations.

"Axxess and CAMP share a unified vision of providing technologically innovative solutions for patient health in order to provide the best possible patient care," CAMP CEO Jeb Andrews said. "From the moment of our initial meeting, I knew we had a shared understanding of missions and values. We could not be more excited to partner with Axxess to fulfill the vision of helping as many patients and families suffering from cognitive impairment as possible. We wanted to partner with the right team, and we know we have done just that." 

About Axxess? 

Axxess is the leading technology innovator for healthcare at home, focused on solving the most complex industry challenges. Trusted by more than 9,000 organizations that serve more than 3 million patients worldwide, Axxess offers a complete suite of easy-to-use software solutions that empower home health, home care, hospice, and palliative providers to make healthcare in the home human again. The company's collaborative culture focused on innovation and excellence is recognized nationally as a "Best Place to Work." 

About CAMP

CAMP is a first-of-its-kind digital cognitive rehabilitation program monitored by physicians and delivered by home health clinicians or therapists. CAMP is designed to help patients with mild-to-moderate cognitive impairments including Dementia, Alzheimer's, TBI, Chemo Brain, Age-related Memory Loss, and other common cognitive deficits. CAMP provides in-depth training and support so home health RNs, LPs, STs, and/or OTs can become CAMP certified and begin delivering cognitive rehabilitation treatments managed through our system.

Axxess Contact: Dennis Petroskey
(202) 215-6767 
[email protected]

CAMP Contact: Mollie Cline
(800) 514-9091 
[email protected]

SOURCE Axxess


These press releases may also interest you

at 07:30
Quipt Home Medical Corp. (the "Company") ?, a U.S. based home medical equipment provider, focused on end-to-end respiratory care, announced today that the Toronto Stock Exchange ("TSX") has accepted the Company's notice of intention to implement a...

at 07:30
Theratechnologies Inc. ("Theratechnologies" or the "Company") , a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will present long-term efficacy, safety and...

at 07:30
MedBright AI Investments Inc. (the "Company" or "MedBright") today announced MedMatrix, a product in which it has a significant investment, has launched two new demonstration videos highlighting the capabilities of the MedMatrix AI Reporter and...

at 07:30
End-of-treatment data from two Phase 2a combination clinical trials with imdusiran to be presented at the EASL Congress in June 2024 Preliminary data from the single-dose portion of the AB-101-001 clinical trial show that AB-101 was generally...

at 07:30
VitalHub Corp. (the "Company" or "VitalHub") is pleased to announce that it will release its financial results for its first quarter 2024 ended March 30th, 2024, after market close on May 9th, 2024. The Company will subsequently hold a conference...

at 07:25
Arbutus Biopharma Corporation ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today...



News published on and distributed by: